Oligonucleotides CMC and Analytical Development Summit Hilton Boston Back Bay, Boston

The 2nd Oligonucleotides CMC and Analytical Development Summit returns this August to Boston.

With the unprecedented growth of the oligonucleotides market, reaching $2b by 2027 and with over 250 in the clinical phase of drug development, we now seek to unlock the potential of oligonucleotides beyond rare disease to treat large patient populations for undruggable targets.

In the last 12 months alone, there have been a number of advances in the field with Switch Therapeutics advancing their first RNAi technology, Avidity turbocharging their antibody-oligo conjugate and Ansa Biotech successfully synthesising the world’s longest oligonucleotide! Despite this, drug developers still face challenges in manufacturability and lack of concrete regulatory protocols.

Across 3 days, senior leaders will leverage knowledge and share thought leadership focused on improving analytical characterization, effectively preparing CMC data for IND filing and scaling up with long-term manufacturing in mind.

Built with experts from AstraZeneca, Alexion Pharmaceuticals and Biogen, revolutionize your drug development protocols by keeping your finger on the pulse at this hotly anticipated summit. With the market sky-rocketing and pipelines developing, this is your chance to be at the cutting edge!